Citius Oncology announced a registered direct offering and private placement to raise $18 million.
The funds will strengthen the company's cash position and support the commercial launch of LYMPHIR™.
LYMPHIR™ is a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL).
Offering Details
1,284,404 shares of common stock at $1.09 per share in a registered direct offering, along with warrants to purchase more shares.
Private Placement
15,229,358 shares of common stock (or pre-funded warrants) and accompanying warrants at $1.09 per share.
Placement Agent
H.C. Wainwright & Co. is the exclusive placement agent for the offerings.
- The offerings are expected to close around December 10, 2025.
- The net proceeds will be used for the commercial launch of LYMPHIR™ and general corporate purposes.
Citius Oncology's successful offering will provide the necessary funds for its strategic initiatives, including launching LYMPHIR™.